Skip to content

Study · Non-randomized trial · n = 6 · 1990

4 results

Ventilatory effects of substance P, vasoactive intestinal peptide, and nitroprusside in humans.

Maxwell DL, Fuller RW, Dixon CM, Cuss FM, Barnes PJ

Journal of applied physiology (Bethesda, Md. : 1985)1 Jan 1990Cited by 11 (Europe PMC)

PMID1690202 (opens in a new tab)DOI10.1152/jappl.1990.68.1.295 (opens in a new tab)PepBankPUB-01690202
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In six normal humans, VIP infusion caused significantly less hypotension than nitroprusside.

    In plain wordsIn healthy people, VIP infusion lowered blood pressure less than nitroprusside did.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseHypotension compared with nitroprusside
    Study

    n = 6

    Comparator
    Nitroprusside
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    6 pmol.kg-1.min-1As given in this study (human).

    Source sentences

    Summary
    Both peptides caused significantly less hypotension than nitroprusside.
    2 context sentences
    Summary · context
    Infusions of substance P (1 pmol.kg-1.min-1) and of VIP (6 pmol.kg-1.min-1) were compared with placebo and with nitroprusside (5 micrograms.kg-1.min-1) as a control for the hypotensive action of the peptides.
    Summary · context
    The effects of these peptides on resting ventilation and on ventilatory responses to hypoxia and to hypercapnia have been investigated in six normal humans.
  2. 02HumanNon-randomized trialActivity measurement

    In six normal humans, increases in ventilation were significantly greater with substance P and nitroprusside than with VIP.

    In plain wordsIn healthy people, substance P and nitroprusside raised breathing more than VIP did.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseResting ventilation
    Study

    n = 6

    Comparator
    Nitroprusside and substance P
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    6 pmol.kg-1.min-1As given in this study (human).

    Source sentences

    Summary
    Substance P and nitroprusside caused significantly greater increases in ventilation and in the hypoxic ventilatory response than VIP.
    1 context sentence
    Summary · context
    The effects of these peptides on resting ventilation and on ventilatory responses to hypoxia and to hypercapnia have been investigated in six normal humans.
  3. 03HumanNon-randomized trialActivity measurement

    In six normal humans, increases in the hypoxic ventilatory response were significantly greater with substance P and nitroprusside than with VIP.

    In plain wordsIn healthy people, substance P and nitroprusside raised the breathing response to low oxygen more than VIP did.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseHypoxic ventilatory response
    Study

    n = 6

    Comparator
    Nitroprusside and substance P
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    6 pmol.kg-1.min-1As given in this study (human).

    Source sentences

    Summary
    Substance P and nitroprusside caused significantly greater increases in ventilation and in the hypoxic ventilatory response than VIP.
    1 context sentence
    Summary · context
    The effects of these peptides on resting ventilation and on ventilatory responses to hypoxia and to hypercapnia have been investigated in six normal humans.
  4. 04HumanNon-randomized trialActivity measurement

    In six normal humans, no changes in hypercapnic sensitivity were seen with VIP, substance P or nitroprusside infusion.

    In plain wordsIn healthy people, the breathing response to raised carbon dioxide did not change during the infusions.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeHypercapnic sensitivity
    Study

    n = 6

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    6 pmol.kg-1.min-1As given in this study (human).

    Source sentences

    Summary
    No changes were seen in hypercapnic sensitivity.
    1 context sentence
    Summary · context
    The effects of these peptides on resting ventilation and on ventilatory responses to hypoxia and to hypercapnia have been investigated in six normal humans.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.